Another important study, including 732 MM patients treated with BRAF+/−MEKi inside four clinical trials [110], is in agreement with previous findings that the presence of mutant BRAF ctDNA at baseline is associated with worse clinical outcomes in MM patients treated with BRAF/MEKi. This evidence concerns the gene BRAF and Miyoshi myopathy.